AbbVie Enters into an Exclusive Option and License Agreement for HPN217 and Expands its Existing Collaboration with Harpoon Therapeutics

 AbbVie Enters into an Exclusive Option and License Agreement for HPN217 and Expands its Existing Collaboration with Harpoon Therapeutics

AbbVie Enters into an Exclusive Option and License Agreement for HPN217 and Expands its Existing Collaboration with Harpoon Therapeutics

Shots:

  • As per the option and license agreement, Harpoon to receive up to $510M as up front, option payments and milestones with royalties on sales and will conduct development of HPN217 till P-I/II. AbbVie to get an option to license exclusive WW rights of HPN217, if exercises the option, will be responsible for all development & commercialization activities
  • Under the expanded collaboration, Harpoon to receive up to $310M/target as up front, milestones with royalties on sales. AbbVie to get exclusive WW rights to develop and commercialize two new therapies developed utilizing Harpoon’s TriTAC platform and has an option to select up to 4 additional therapies out of 6
  • Additionally, Harpoon and AbbVie will jointly conduct research activities for each selected therapy while AbbVie will exclusively responsible for development & commercial activities of each therapy

Click here to­ read full press release/ article | Ref: AbbVie | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post